Alectinib and Bevacizumab

The combination therapy consists of alectinib, a second-generation ALK tyrosine kinase inhibitor, and bevacizumab, an anti-VEGF monoclonal antibody. This combination has shown significant efficacy in clinical trials, particularly the ALEK-B phase 2 trial. Alectinib works by inhibiting the aberrant tyrosine kinase activity resulting from ALK fusion proteins, which drive proliferation and survival in affected cancer cells. Bevacizumab targets vascular endothelial growth factor A (VEGF-A), a pivotal mediator of angiogenesis. By neutralizing VEGF-A, bevacizumab reduces neovascularization, consequently impairing tumor oxygenation and nutrient supply. The rationale for combining these agents rests on the hypothesis that suppressing both the molecular oncogenic driver and its supportive microenvironment yields synergistic antitumor effects stronger than monotherapies alone. Key findings from the ALEK-B trial (NCT03779191) include: - 12-month progression-free survival (PFS) rate of 97.1% (95% CI 92.6-100) - 36-month PFS rate of 64.2% (95% CI 56.1-85.2) - 36-month overall survival (OS) rate of 87.9% (95% CI 74-96.6) - 100% objective response rate (ORR) - 36-month intracranial PFS rate of 87.8% (95% CI 74.0-96.6) The combination therapy demonstrated a manageable safety profile: - Grade 3-4 adverse events occurred in 46.3% of patients - Most common adverse events included diarrhea (75.6%), proteinuria (70.7%), and anemia (58.5%) - Most common grade 3-4 adverse events were proteinuria (22.0%), alanine aminotransferase increase (17.1%), and aspartate aminotransferase increase (9.8%) - No fatal adverse events were reported - Proteinuria led to bevacizumab discontinuation in 43.9% of patients Patient-reported quality of life significantly improved from baseline at 12 months and was maintained through 36 months. The treatment maintained quality of life improvements throughout the study period despite higher rates of adverse events compared to alectinib monotherapy.